Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Imatinib

Imatinib Phase 3 dose trials (combined analysis on label)

Novartis · Phase 3 · Completed · Enrollment 1640

Registry id n/r

ArmReported safety
Imatinib 400 mg dailyn/r
Imatinib 800 mg dailyn/r

A count stays a count. This page does not turn a count into a percent.